MedTrace Logo

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

NCT00050687 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2011-01-28

No results posted yet for this study

Summary

This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.

Conditions

Interventions

DRUG

Gallium maltolate

Sponsors & Collaborators

  • Titan Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050687 on ClinicalTrials.gov